Scientists are making waves with a novel therapy for metastatic colorectal cancer (mCRC) that combines two powerful antibodies—one targeting epidermal growth factor receptor (EGFR), the other ...
产品活性: Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 ...
Researchers have found a new receptor for nerve growth factor that plays an important role in pain signaling, even though it does not signal on its own, according to a new study. The findings hold ...
Among Asian Americans, lung cancer rates have been rising in the past several decades with no smoking history. Dr. Bryant […] ...
Elena Shagisultanova, MD, PhD, is working to uncover effective treatments for HER2-positive breast cancer patients by combining different drugs to counteract the cancer cells’ proliferation.
Reveal Genomics and the Istituto Europeo di Oncologia (IEO) have initiated an impact study of the genomic test, HER2DX, to ...
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients ...
In August, the FDA approved Imfinzi (durvalumab) in combination with chemotherapy for adult patients with resectable ...
The FDA is expected to decide on treatments for EBV-positive posttransplant lymphoproliferative disease, breast cancer, Barth syndrome, pain, and migraine.